<DOC>
	<DOCNO>NCT01242267</DOCNO>
	<brief_summary>The primary objective study : • Determine maximum tolerate dose thalidomide use conjunction dose-intense melphalan , bortezomib autologous ( syngeneic ) HSC support salvage therapy patient fail prior treatment dose-intense melphalan The secondary objective study : - Determine toxicity result administration combination thalidomide , bortezomib melphalan - Determine complete response ( CR ) good partial response ( VgPR ) rate patient undergo ASCT use thalidomide , bortezomib melphalan - Evaluate treatment-free interval treatment combination thalidomide , bortezomib melphalan</brief_summary>
	<brief_title>Escalating Doses Thalidomide Conjunction With Bortezomib HIgh Dose Melphalan BSCT</brief_title>
	<detailed_description>VELCADE™ ( bortezomib ) Injection small molecule proteasome inhibitor develop Millennium Pharmaceuticals , Inc. , ( Millennium ) novel agent treat human malignancy . VELCADE currently approve United States Food Drug Administration ( US FDA ) register Europe treatment multiple myeloma patient receive least one prior therapy . By inhibit single molecular target , proteasome , bortezomib affect multiple signal pathway . The anti-neoplastic effect bortezomib likely involve several distinct mechanism , include inhibition cell growth survival pathway , induction apoptosis , inhibition expression gene control cellular adhesion , migration angiogenesis . Thus , mechanism bortezomib elicits antitumor activity may vary among tumor type , extent affect pathway critical inhibition tumor growth could also differ . Bortezomib novel pattern cytotoxicity National Cancer Institute ( NCI ) vitro vivo assay ( Adams et al. , 1999 ) . In addition , bortezomib cytotoxic activity variety xenograft tumor model , single agent combination chemotherapy radiation ( Steiner et al. , 2001 ; Teicher et al. , 1999 ; Cusack et al. , 2001 ; LeBlanc et al. , 2002 ; Pink et al. , 2002 ) . Notably , bortezomib induces apoptosis cell express bcl-2 , genetic trait confers unregulated growth resistance conventional chemotherapeutics ( McConkey et al. , 1999 ) . Bortezomib think efficacious multiple myeloma via inhibition nuclear factor κB ( NF-κB ) activation , attenuation interleukin-6 ( IL-6 ) -mediated cell growth , direct apoptotic effect , possibly anti-angiogenic effect .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Female subject either postmenopausal surgically sterilize willing use acceptable method birth control describe S.T.E.P.S program . Participation program require . Male subject agrees use acceptable method contraception duration study describe S.T.E.P.S program . Participation program require . Confirmed diagnosis multiple myeloma , plasma cell leukemia . Show progression disease previous doseintense cycle melphalan , less complete response prior cycle doseintense melphalan . Patients may receive prior autologous transplant highdose melphalan . May receive intervene therapy disease progression doseintense melphalan enrollment protocol . Recovery complication salvage therapy , administer . Age : ≥18 yr &lt; 76 yrs time melphalan administration . Gender : There gender restriction . Availability &gt; 2x106 autologous peripheral blood CD34+ cells/kg syngeneic donor meeting eligibility criterion syngeneic donation . 1 . Syngeneic transplantation prefer . Patients meet follow exclusion criterion enrol study . Cytotoxic chemotherapy radiotherapy within 21 day initiate treatment study . Prior doseintense therapy within 56 day initiate treatment study . Uncontrolled bacterial , viral , fungal parasitic infection . Uncontrolled CNS metastasis . Known amyloid deposition heart . Organ dysfunction : LVEF &lt; 40 % cardiac failure responsive therapy . DLCO &lt; 50 % predict and/or receive supplementary continuous oxygen . Evidence hepatic synthetic dysfunction , total bilirubin &gt; 2x AST &gt; 3x ULN . Measured creatinine clearance &lt; 20 ml/min . Sensory peripheral neuropathy grade 4 within 14 day enrollment . Karnofsky score &lt; 70 % unless result bone disease directly cause myeloma . Life expectancy limit another comorbid illness . Diagnosed treat another malignancy within 2 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Female subject pregnant breastfeeding ( woman ) unwilling use acceptable birth control method ( men woman ) twelve month treatment unwilling participate S.T.E.P.S program . Documented hypersensitivity melphalan , thalidomide bortezomib , boron mannitol component formulation Patients unable unwilling provide consent Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . Patient receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>transplant</keyword>
	<keyword>Multiple myeloma patient undergoing transplant</keyword>
</DOC>